+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007-2014



Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007-2014



Vaccine 36(23): 3381-3386



In the United States, the Advisory Committee on Immunization Practices (ACIP) has recommended routine human papillomavirus (HPV) vaccination at age 11-12 years since 2006 for girls and since 2011 for boys. ACIP also recommends vaccination through age 26 for females and through age 21 for males; males may be vaccinated through age 26. We describe vaccine uptake in adolescents and young adults using data from MarketScan Commercial Claims and Encounters. We analyzed data on persons aged 11-26 years on December 31, 2014 who were continuously enrolled in a MarketScan health plan from age 11 through year 2014, or from 2006 to 2014 if aged ≥11 years in 2006 (916,513 females, 951,082 males). Individuals were grouped based on their age (years) in 2014: 11-12 (born 2002-03), 13-14 (2000-01), 15-16 (1998-99), 17-18 (1996-97), 19-21 (1993-95), and 22-26 (1988-1992). We calculated cumulative coverage with ≥1 HPV vaccine dose by sex, birth cohort, and calendar year. In females, the proportion initiating vaccination at age 11-12 years was low in 2008 and 2010 (12.6% and 11.1%) and higher in 2012 (15.7%) and 2014 (19.5%); in males, initiation at age 11-12 was 0.9% in 2010, 8.3% in 2012, and 15.1% in 2014. In females who aged into vaccine eligibility, cumulative coverage by 2014 was higher in older cohorts (17-18: 53%; 15-16: 47%; 13-14: 39%; 11-12: 19.5%). For males, cumulative coverage by 2014 was similar in those aged 13-14, 15-16, and 17-18 years (28.9%, 32.5%, 30.3%), and lower in those aged 11-12 (15.1%), 19-21 (18.4%), and 22-26 years (4.5%). The proportion of males and females initiating vaccination at the recommended ages was low. Although more females than males were vaccinated in all cohorts, the male-female differences were smaller in younger than older cohorts. The trajectory of male vaccination uptake could signal higher acceptability in males.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065205672

Download citation: RISBibTeXText

PMID: 29735321

DOI: 10.1016/j.vaccine.2018.03.045


Related references

Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016. Vaccine 36(19): 2567-2573, 2018

Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. Mmwr. Morbidity and Mortality Weekly Report 63(29): 620-624, 2014

Human Papillomavirus (HPV) Vaccination during well-Child visits in privately insured Males 9-21 years of age in the United States in 2012. Value in Health 18(3): A266-A267, 2015

Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Human Vaccines and Immunotherapeutics 10(1): 232-237, 2014

What explains the different rates of human papillomavirus vaccination among adolescent males and females in the United States?. Papillomavirus Research 2: 46-51, 2016

Ecological Association of Human Papillomavirus Vaccination with Cervical Dysplasia Prevalence in the United States, 2007-2014. American Journal of Public Health 106(12): 2211-2218, 2016

Prevalence of Genital Human Papillomavirus Among Sexually Experienced Males and Females Aged 14-59 Years, United States, 2013-2014. Journal of Infectious Diseases 217(6): 869-877, 2018

Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014. Journal of Infectious Diseases 216(5): 594-603, 2017

Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. Mmwr. Morbidity and Mortality Weekly Report 62(29): 591-595, 2013

Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014. Journal of Infectious Diseases 215(7): 1070-1079, 2017

Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014. Clinical Infectious Diseases 64(2): 144-149, 2016

Trends in Incidence of ACL Reconstruction and Concomitant Procedures Among Commercially Insured Individuals in the United States, 2002-2014. Sports Health 10(6): 523-531, 2018

Factors associated with genital human papillomavirus infection among adult females in the United States, NHANES 2007-2010. Bmc Research Notes 7: 544, 2015

Trends in Inpatient and Outpatient Hysterectomy and Oophorectomy Rates Among Commercially Insured Women in the United States, 2000-2014. JAMA Surgery 151(9): 876-877, 2018

Public health impact of Rotarix vaccination among commercially insured children in the United States. Vaccine 35(37): 5065-5072, 2017